Drug Trial Radar · NCT04452591
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Oct 27, 2020
Primary completion
Jun 16, 2030
Study completion Dec 24, 2031
Sponsor
- Lead sponsor
- CG Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment Cohort C and Cohort P will be analyzed and reported separately. Patients will have had to fail prior BCG therapy which is defined as having persistent or recurrent disease within 12 months (Cohort C) or 6 months (Cohort P) following the completion of adequate BCG therapy for HGUC
Conditions
- Non Muscle Invasive Bladder Cancer
- High-grade Ta/ T1 Papillary Disease Bladder Cancer
Interventions
Cretostimogene GrenadenorepvecBiological
Engineered Oncolytic Adenovirus
n-dodecyl-B-D-maltosideOther
Transduction-enhancing agent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort C:Time frame: 36 months
- Cohort P:Time frame: 36 months
Locations
86 sites in 6 countries. Site status is shown where the registry gives one.
Urology Centers Alabama
Homewood, Alabama
BCG Oncology
Phoenix, Arizona
Mayo Clinic Cancer Center
Phoenix, Arizona
Arizona Institute of Urology
Tucson, Arizona
Arkansas Urology
Little Rock, Arkansas
University of California - Irvine
Irvine, California
American Insititute of Research
Los Angeles, California
Genesis Research
Sherman Oaks, California
Genesis Research LLC
Torrance, California
University of Colorado
Aurora, Colorado
Colorado Clinical Research
Lakewood, Colorado
Urology Associates, Research Department
Lone Tree, Colorado
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Mayo Clinic - Jacksonville
Jacksonville, Florida
Moffit Cancer Center
Tampa, Florida
Emory University
Atlanta, Georgia
Urology Indiana LLC
Greenwood, Indiana
The University of Kansas Cancer Center
Westwood, Kansas
Wichita Urology
Wichita, Kansas
Southern Urology
Lafayette, Louisiana
Chesapeake Urology
Hanover, Maryland
Chesapeake Urology
Severna Park, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Mayo Rochester
Rochester, Minnesota
Mercy Medical Center
St Louis, Missouri
Washington University
St Louis, Missouri
Specialty Clinical Research of St. Louis
St Louis, Missouri
New Jersey Premier Urology
Edison, New Jersey
Our Lady of Lourdes
Binghamton, New York
Stony Brook University
Stony Brook, New York
Montifiore Medical Center
The Bronx, New York
Duke University
Durham, North Carolina
Wake Forest
Winston-Salem, North Carolina
University of Toledo
Toledo, Ohio
Keystone Urology Specialists
Lancaster, Pennsylvania
University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania
Prisma Health - Regional Urology
Greenville, South Carolina
Carolina Urologic Research Center LLC
Myrtle Beach, South Carolina
Conrad Pearson Clinic
Germantown, Tennessee
Urology Associates- Nashville
Nashville, Tennessee
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.